In particular, small molecules and monoclonal antibodies targeting CSF-1/CSF-1R signaling have been found to decrease macrophage infiltration and the cancer stem cell pool, enabling the restoration of the antitumor activity of the cytotoxic T cells [37,38]; their clinical efficacy is under investigation in several ongoing clinical trials [36]. Here, CSF1 is linked to cancer.